Latest Profitability News

Region Group reported steady financial results for the first half of FY25, maintaining AFFO guidance and achieving a statutory net profit of $81.8 million, underpinned by strong tenant retention and targeted portfolio enhancements.

Region Group reports a robust first half of FY25 with $81.8 million net profit and an 8% growth in assets under management, underpinned by stable occupancy and strategic capital recycling.

Region Group has reported a remarkable turnaround with an $81.8 million net profit for the half year ended December 2024, reversing last year's loss while maintaining its interim distribution at 6.70 cents per security.

Macquarie Group’s 3Q25 trading update reveals strong growth in its annuity-style businesses, while markets-facing segments face pressure from subdued commodity markets, resulting in a mixed financial performance for the year to date.

Breville Group Limited delivered a robust first half for FY25, posting double-digit revenue growth and a significant rise in net profit, underpinned by strong consumer demand and proactive inventory management to counter tariff risks.

Breville Group Limited has announced a fully franked ordinary dividend of AUD 0.18 per share for the six months ending December 31, 2024, signaling steady shareholder returns.

Breville Group Limited reported a robust half-year performance with 10.1% revenue growth and a 16.1% rise in net profit, driven by strong coffee category sales and strategic product launches. Despite macroeconomic headwinds and tariff concerns, the company maintains a confident outlook for FY25.

Breville Group Limited reported a robust half-year performance with a 10.1% rise in revenue to nearly A$1 billion and a 16.1% jump in net profit, underpinning confidence in its premium appliance strategy.

Macquarie Group's 3Q25 trading update reveals strong growth in annuity-style businesses offset by a significant decline in markets-facing segments due to subdued commodity markets. The group's capital position remains robust, comfortably exceeding regulatory requirements.

CSL Limited reported a solid half-year performance with 5% revenue growth and a 7% rise in net profit, driven by strong demand in its Behring and Vifor segments despite challenges in Seqirus. The company reaffirmed its full-year NPATA guidance of 10-13%, signaling confidence in its operational momentum.

CSL Limited posted a robust half-year performance with NPATA rising 5% at constant currency, driven by strong growth in CSL Behring and CSL Vifor despite challenges in its influenza vaccine segment. The company reaffirmed its FY25 guidance, anticipating double-digit earnings growth.

CSL Limited reported a solid 5% revenue increase and 6% rise in net profit after tax for the half year ended December 2024, underpinned by robust performance in its plasma therapies business despite headwinds in its influenza vaccine segment.